dm+d

16591711000001109

Articles

Safety in Lactation: Gout and cytotoxic-induced hyperuricaemia

21 October 2020Colchicine and canakinumab are normally used to treat the symptoms of acute attacks of gout. Allopurinol, febuxostat and sulfinpyrazone are used for the long-term control…

Safety in Lactation: Other immunomodulating drugs

21 September 2020Several drugs in this section (dimethyl fumerate, interferon beta, fingolimod, glatiramer, natalizumab) are used in multiple sclerosis (MS) but are not normally interchangeable as they…
Search Articles

Refrigerated Storage

IlarisNovartis Pharmaceuticals

Novartis Pharmaceuticals
Ilaris
150mg powder for solution for injection (vial)

Contact Novartis Medical Information in all cases where a deviation from the recommended storage conditions has occurred.

Details of the temperature excursion and the product batch number will be requested.

Refer to the current BNF for company contact details

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

14 May 2020
London Medicines Information Service

Lactation Safety Information

For inherited auto-inflammatory disorders

For inherited auto-inflammatory disorders
-
No published evidence of safety
Low levels anticipated in milk due to the drug’s properties. However, long half-life increases risk of accumulation in breastfed infants
Although large protein molecules may appear in colostrum, risk to preterm infants and neonates is considered to be small and unproven
17 September 2020

For acute gout

For acute gout
NSAIDs
No published evidence of safety
Low levels anticipated in milk due to the drug’s properties. However, long half-life increases risk of accumulation in breastfed infants
Although large protein molecules may appear in colostrum, risk to preterm infants and neonates is considered to be small and unproven
17 September 2020

New Medicines

Ilaris Metastatic non-small cell lung cancer (NSCLC) - first-line maintenance therapy

Information

Ilaris
Licence extension / variation
Novartis
Novartis

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Interleukin 1-beta antagonist, first-in-class in non-small cell lung cancer
The incidence rate of lung cancer in 2006 was 72.2 per 100,000 in men and 50.8 per 100,000 in women. Lung cancer belongs to the three most common cancers in men (14.8 % of all cancers) and women (10.9% of all cancers).
Metastatic non-small cell lung cancer (NSCLC) - first-line maintenance therapy
Subcutaneous injection

IlarisNon-small cell lung cancer (NSCLC), II-IIIA and the subset of IIIB (T>5cm N2 disease) completely resected - adjuvant therapy

Information

Ilaris
Licence extension / variation
Novartis
Novartis

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Interleukin 1-beta antagonist, first-in-class in non-small cell lung cancer
The incidence rate of lung cancer in 2006 was 72.2 per 100,000 in men and 50.8 per 100,000 in women. Lung cancer belongs to the three most common cancers in men (14.8 % of all cancers) and women (10.9% of all cancers)
Non-small cell lung cancer (NSCLC), II-IIIA and the subset of IIIB (T>5cm N2 disease) completely resected - adjuvant therapy
Subcutaneous injection

Ilaris Metastatic non-small cell lung cancer (NSCLC) - second- or third-line

Information

Ilaris
Licence extension / variation
Novartis
Novartis

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Apr 21Development discontinued [6].

Category

Interleukin 1-beta antagonist, first-in-class in non-small cell lung cancer
The incidence rate of lung cancer in 2006 was 72.2 per 100,000 in men and 50.8 per 100,000 in women. Lung cancer belongs to the three most common cancers in men (14.8 % of all cancers) and women (10.9% of all cancers).
Metastatic non-small cell lung cancer (NSCLC) - second- or third-line
Subcutaneous injection

Trial or other data

Mar 21PIII CANOPY-2 trial of canakinumab failed to meet the primary endpoint of overall survival (OS). The company plans to continue to analyse the data. [5]